AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Netherlands and Ireland become the latest countries to pause the rollout of the AstraZeneca vaccine as a precautionary measure.

AstraZeneca defends COVID-19 vaccine after more countries suspend its use over blood clot concerns

The Netherlands has paused the use of AstraZeneca's COVID-19 vaccine as a precaution while investigators look into cases of blood clots among vaccinated people. Dutch health minister Hugo de Jonge said Sunday that the suspension would last at least two weeks, as the country awaits further guidance from the European Medicines Agency (EMA), the European regulator.

The Netherlands becomes the 7th country to suspend AstraZeneca's COVID-19 vaccine, pending an investigation into blood clots

The WHO has sought to downplay safety concerns, saying last week that there is no link between the shot and an increased risk of developing blood clots.

Ireland, Netherlands become latest countries to suspend AstraZeneca vaccine

AstraZeneca PLC's (LON:AZN) has defended its COVID-19 vaccine after it was suspended in the Netherlands and the Republic of Ireland. The Dutch government said the decision was taken as a precaution and the halt will last until March 29.

AstraZeneca defends COVID-19 vaccine after new suspensions in Netherlands, Republic of Ireland

Netherlands and Ireland joined several other countries who have temporarily suspended the rollout of the shots after reports of side effects including blood clots.

AstraZeneca Defends Covid-19 Vaccine Safety As The Netherlands, Ireland Join Others In Suspending Use

AstraZeneca Plc (NASDAQ: AZN) said on Sunday that a review of safety data of more than 17 million people vaccinated with its COVID-19 vaccine in the European Union and the United Kingdom showed no evidence of an increased risk of blood clots. What Happened: According to the drugmaker, the safety data showed no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.

AstraZeneca Review Finds COVID-19 Vaccine Doesn't Increase Risk Of Blood Clots

NEW YORK, March 14, 2021 /PRNewswire/ -- NOTICE: Previous releases about this case cited an incorrect lead plaintiff deadline of March 27. The actual deadline is March 29.

ALERT - LEAD PLAINTIFF DEADLINE CORRECTION: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca plc of Class Action Lawsuit and Upcoming Deadline - AZN

Ireland is the latest country to suspend the use of the AstraZeneca vaccine temporarily.  What Happened: Many European countries now have suspended the use of AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccines after reports of blood clotting problems.

Countries Piling In To Suspend AstraZeneca Vaccine Over Blood-Clotting Concerns

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZeneca To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN) and reminds investors of the March 29, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in AstraZeneca stock or options between May...

AstraZeneca Class Action Reminder

The World Health Organization has urged countries to keep inoculating citizens with AstraZeneca and Oxford University's COVID-19 vaccine as it investigates reports that some people developed blood clots after getting the shot. The agency's Friday statement came as multiple countries paused their use of the vaccine as authorities investigate cases of blood clots found among people who were inoculated with it.

The WHO says countries should keep using AstraZeneca's COVID-19 vaccine as it investigates reports of blood clots

Moderna

Was AstraZeneca Smart to Sell Its Moderna Shares?

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline – AZN

Los Angeles, March 12, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 29, 2021.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

"Just because it's reported following a vaccination doesn't mean that it's because of the vaccination," WHO's chief scientist Dr. Soumya Swaminathan said.

WHO says it's investigating reports of blood clots in people who got AstraZeneca Covid vaccine

The World Health Organization said countries should not stop using AstraZeneca's COVID-19 vaccine amid fears about people who received the jab developing blood clots. In a Friday briefing, WHO spokesperson Margaret Harris said no causal link had been established between the British drugmaker's “excellent” shot and the blood clot cases that have emerged in Europe.

WHO says AstraZeneca COVID vaccine OK to use despite blood clot fears

Europe's COVID-19 vaccine rollout with AstraZeneca Plc (NASDAQ: AZN) has intensified further, with at least nine countries suspending the use of the shot over safety concerns, reports Bloomberg. This latest concern comes on top of the company's already existing supply problem with the EU.

Europe's Vaccination Drive Shaky As Bloc Grapples With Safety Scare Related To AstraZeneca COVID-19 Shot: Report

Thailand delayed the shot's rollout over fears it causes blood clots, despite assurances from regulators that there is no evidence linking the vaccine to the incidents.

Experts Defend Safety Of AstraZeneca Covid-19 Vaccine After Several Countries Suspend The Shot

The European Union has asked AstraZeneca to do more to respect its contract with the bloc, as concerns grow that the firm will miss delivery targets once again.

EU says AstraZeneca is not doing enough to meet its vaccine deliveries target

AstraZeneca has said the vaccine has been studied extensively during Phase 3 trials and peer-reviewed data confirms the shot is "generally well tolerated."

More countries suspend AstraZeneca vaccinations over blood clot fears: What we know so far

Thailand said Friday it had paused use of AstraZeneca's COVID-19 vaccine while investigators looked into potential side effects and adverse reactions, becoming the first Asian country to make the move. Denmark, Norway, and Iceland all said on Thursday they were suspending all use of the vaccine following several cases of blood clots among vaccinated people. Several other European countries, including Italy, have suspended a specific batch of the vaccine.

Thailand follows Denmark in suspending AstraZeneca's COVID-19 vaccine, pending an investigation into possible side effects

Six European countries have temporarily halted distribution of AstraZeneca PLC's (LON:AZN) Covid-19 vaccine due to concern over possible side effects. Denmark today followed Austria, Estonia, Latvia, Lithuania and Luxembourg in pausing the use of a 1mln-dose batch sent to a total of 17 countries within the EU.

AstraZeneca vaccine suspended in Denmark over side effect concerns

The shares of AstraZeneca PLC (NASDAQ:AZN) are down 1.7% to trade at $48.95 this morning, following news that Italy banned the drugmaker's Covid-19 vaccine after two recently inoculated men died in Sicily.

European Pause on AstraZeneca Vaccine Sends Stock Lower

Los Angeles, California--(Newsfile Corp. - March 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive...

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Today, Denmark said it was suspending its use of the Oxford/AstraZeneca vaccine while it was investigating several cases of blood clots among people who had received the jab. Norway followed a few hours later. Let's be clear. To date, all signs point towards AstraZeneca's vaccine working and being safe. Multiple respected regulators cleared it for us, and millions of people have had the shot.

Denmark suspending use of the AstraZeneca COVID-19 jab is another dark cloud over a troubled vaccine

Earlier this week the European drug regulator had said there was no indication that the vaccine caused blood clotting.

News for AstraZeneca Stock (AZN)